NCT06325683 2026-03-18Anti-Lag-3 (Relatlimab) and Anti-PD-1 Blockade (Nivolumab) Versus Standard of Care (Lomustine) for the Treatment of Patients With Recurrent GlioblastomaNational Cancer Institute (NCI)Phase 2 Recruiting184 enrolled